UK consensus on normal tissue dose constraints for stereotactic radiotherapy
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ...
| 主要な著者: | , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
Elsevier
2017
|
| _version_ | 1826281816176197632 |
|---|---|
| author | Hanna, G Murray, L Patel, R Jain, S Aitken, K Franks, K van As, N Tree, A Hatfield, P Harrow, S McDonald, F Ahmed, M Saran, F Webster, G Khoo, V Landau, D Eaton, D Hawkins, M |
| author_facet | Hanna, G Murray, L Patel, R Jain, S Aitken, K Franks, K van As, N Tree, A Hatfield, P Harrow, S McDonald, F Ahmed, M Saran, F Webster, G Khoo, V Landau, D Eaton, D Hawkins, M |
| author_sort | Hanna, G |
| collection | OXFORD |
| description | Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally. |
| first_indexed | 2024-03-07T00:34:29Z |
| format | Journal article |
| id | oxford-uuid:80ecc107-0cf5-4069-bc88-7f94d1cbc6e8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:34:29Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:80ecc107-0cf5-4069-bc88-7f94d1cbc6e82022-03-26T21:26:49ZUK consensus on normal tissue dose constraints for stereotactic radiotherapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:80ecc107-0cf5-4069-bc88-7f94d1cbc6e8EnglishSymplectic Elements at OxfordElsevier2017Hanna, GMurray, LPatel, RJain, SAitken, KFranks, Kvan As, NTree, AHatfield, PHarrow, SMcDonald, FAhmed, MSaran, FWebster, GKhoo, VLandau, DEaton, DHawkins, MSix UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally. |
| spellingShingle | Hanna, G Murray, L Patel, R Jain, S Aitken, K Franks, K van As, N Tree, A Hatfield, P Harrow, S McDonald, F Ahmed, M Saran, F Webster, G Khoo, V Landau, D Eaton, D Hawkins, M UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title | UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title_full | UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title_fullStr | UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title_full_unstemmed | UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title_short | UK consensus on normal tissue dose constraints for stereotactic radiotherapy |
| title_sort | uk consensus on normal tissue dose constraints for stereotactic radiotherapy |
| work_keys_str_mv | AT hannag ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT murrayl ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT patelr ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT jains ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT aitkenk ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT franksk ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT vanasn ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT treea ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT hatfieldp ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT harrows ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT mcdonaldf ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT ahmedm ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT saranf ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT websterg ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT khoov ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT landaud ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT eatond ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy AT hawkinsm ukconsensusonnormaltissuedoseconstraintsforstereotacticradiotherapy |